JP2012517444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517444A5 JP2012517444A5 JP2011549324A JP2011549324A JP2012517444A5 JP 2012517444 A5 JP2012517444 A5 JP 2012517444A5 JP 2011549324 A JP2011549324 A JP 2011549324A JP 2011549324 A JP2011549324 A JP 2011549324A JP 2012517444 A5 JP2012517444 A5 JP 2012517444A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- independently
- aryl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 100
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 82
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 77
- 150000001875 compounds Chemical class 0.000 claims description 73
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 49
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 47
- 125000000623 heterocyclic group Chemical group 0.000 claims description 47
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 125000003107 substituted aryl group Chemical group 0.000 claims description 34
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 32
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 31
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 23
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 150000001721 carbon Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- -1 -C (= O) oR 11 Chemical compound 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 8
- 239000002777 nucleoside Substances 0.000 claims description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 8
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 claims description 4
- 241000710781 Flaviviridae Species 0.000 claims description 4
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims description 4
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims description 4
- 241000711549 Hepacivirus C Species 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 239000002841 Lewis acid Substances 0.000 claims description 4
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- 229940124615 TLR 7 agonist Drugs 0.000 claims description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 150000007517 lewis acids Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 102000001493 Cyclophilins Human genes 0.000 claims description 3
- 108010068682 Cyclophilins Proteins 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 241000710912 Kunjin virus Species 0.000 claims description 2
- 241000710908 Murray Valley encephalitis virus Species 0.000 claims description 2
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 claims description 2
- 241000710888 St. Louis encephalitis virus Species 0.000 claims description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 241000710886 West Nile virus Species 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 241000907316 Zika virus Species 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 150000002902 organometallic compounds Chemical class 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 239000000134 cyclophilin inhibitor Substances 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910019946 S-S Inorganic materials 0.000 description 1
- 229910019939 S—S Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15124809P | 2009-02-10 | 2009-02-10 | |
| US61/151,248 | 2009-02-10 | ||
| PCT/US2010/023586 WO2010093608A1 (en) | 2009-02-10 | 2010-02-09 | Carba-nucleoside analogs for antiviral treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014139374A Division JP5951690B2 (ja) | 2009-02-10 | 2014-07-07 | 抗ウイルス処置のためのカルバ−ヌクレオシドアナログ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012517444A JP2012517444A (ja) | 2012-08-02 |
| JP2012517444A5 true JP2012517444A5 (enExample) | 2013-03-07 |
| JP5746638B2 JP5746638B2 (ja) | 2015-07-08 |
Family
ID=42333309
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549324A Expired - Fee Related JP5746638B2 (ja) | 2009-02-10 | 2010-02-09 | 抗ウイルス処置のためのカルバ−ヌクレオシドアナログ |
| JP2014139374A Expired - Fee Related JP5951690B2 (ja) | 2009-02-10 | 2014-07-07 | 抗ウイルス処置のためのカルバ−ヌクレオシドアナログ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014139374A Expired - Fee Related JP5951690B2 (ja) | 2009-02-10 | 2014-07-07 | 抗ウイルス処置のためのカルバ−ヌクレオシドアナログ |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8012942B2 (enExample) |
| EP (2) | EP2396340B1 (enExample) |
| JP (2) | JP5746638B2 (enExample) |
| KR (2) | KR101834707B1 (enExample) |
| CN (1) | CN102348713B (enExample) |
| AP (1) | AP2922A (enExample) |
| AU (3) | AU2010213873B2 (enExample) |
| BR (1) | BRPI1013643A2 (enExample) |
| CA (1) | CA2751277C (enExample) |
| CL (1) | CL2011001906A1 (enExample) |
| CO (1) | CO6420354A2 (enExample) |
| DK (1) | DK2396340T3 (enExample) |
| EA (1) | EA025085B1 (enExample) |
| ES (2) | ES2628842T3 (enExample) |
| HR (1) | HRP20140219T1 (enExample) |
| IL (1) | IL214396A (enExample) |
| MX (2) | MX2011008409A (enExample) |
| NZ (1) | NZ594370A (enExample) |
| PE (3) | PE20161067A1 (enExample) |
| PL (1) | PL2396340T3 (enExample) |
| PT (2) | PT2396340E (enExample) |
| SG (1) | SG173186A1 (enExample) |
| SI (1) | SI2396340T1 (enExample) |
| SM (1) | SMT201400056B (enExample) |
| UA (2) | UA112140C2 (enExample) |
| WO (1) | WO2010093608A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| AU2009240630B2 (en) | 2008-04-23 | 2013-07-18 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| TWI483950B (zh) * | 2009-09-21 | 2015-05-11 | Gilead Sciences Inc | 用於製備１’－取代碳核苷類似物之方法及中間物 |
| WO2012012465A1 (en) | 2010-07-19 | 2012-01-26 | Clarke, Michael, O'neil Hanrahan | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| PH12013500035A1 (en) | 2010-07-22 | 2013-03-11 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
| WO2012039791A1 (en) * | 2010-09-20 | 2012-03-29 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013084165A1 (en) * | 2011-12-05 | 2013-06-13 | Medivir Ab | Hcv polymerase inhibitors |
| NZ628515A (en) | 2012-02-10 | 2016-06-24 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US9109001B2 (en) | 2012-05-22 | 2015-08-18 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphoramidate prodrugs for HCV infection |
| WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
| GEP20176800B (en) | 2012-05-22 | 2018-01-10 | Idenix Pharmaceuticals Llk | D-amino acid compounds for liver disease |
| WO2013174962A1 (en) | 2012-05-25 | 2013-11-28 | Janssen R&D Ireland | Uracyl spirooxetane nucleosides |
| EP2900682A1 (en) | 2012-09-27 | 2015-08-05 | IDENIX Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| CN111848711A (zh) | 2012-10-08 | 2020-10-30 | 埃迪尼克斯医药有限责任公司 | 用于hcv感染的2′-氯核苷类似物 |
| US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
| US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
| EP2970358B1 (en) | 2013-03-04 | 2021-06-30 | Idenix Pharmaceuticals LLC | 3'-deoxy nucleosides for the treatment of hcv |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| US20140271547A1 (en) | 2013-03-13 | 2014-09-18 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
| WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
| EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| CN105814068B (zh) * | 2014-02-27 | 2017-08-04 | 四川海思科制药有限公司 | 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用 |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| SG10202105371YA (en) | 2014-12-26 | 2021-07-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| GEAP202215528A (en) | 2015-03-06 | 2022-11-10 | Atea Pharmaceuticals Inc | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| CN107709344B (zh) * | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | 用于治疗黄病毒科病毒和癌症的核苷类似物 |
| SG10202109869XA (en) | 2015-09-16 | 2021-10-28 | Gilead Sciences Inc | Methods for treating arenaviridae and coronaviridae virus infections |
| CN106083962B (zh) * | 2016-06-08 | 2018-12-18 | 成都倍特药业有限公司 | 一种具有环磷酰胺结构的化合物及其制备方法 |
| LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| BR112019004297A2 (pt) | 2016-09-07 | 2019-05-28 | Atea Pharmaceuticals Inc | método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica. |
| SG11201906163TA (en) | 2017-02-01 | 2019-08-27 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| ES2938859T3 (es) | 2017-05-01 | 2023-04-17 | Gilead Sciences Inc | Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| FI3706762T3 (fi) | 2017-12-07 | 2024-12-13 | Univ Emory | N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| WO2020157694A1 (en) * | 2019-02-01 | 2020-08-06 | Janssen Biopharma, Inc. | Antiviral nucleosides and derivatives thereof |
| CN118662520A (zh) | 2020-01-27 | 2024-09-20 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| US11613553B2 (en) | 2020-03-12 | 2023-03-28 | Gilead Sciences, Inc. | Methods of preparing 1′-cyano nucleosides |
| EP4132651B1 (en) | 2020-04-06 | 2026-03-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| EP4172160A2 (en) | 2020-06-24 | 2023-05-03 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| HUE067491T2 (hu) * | 2020-08-27 | 2024-10-28 | Gilead Sciences Inc | Vegyületek és eljárások vírusfertõzések kezelésére |
| US12558364B2 (en) | 2021-01-20 | 2026-02-24 | Regents Of The University Of Minnesota | Next generation remdesivir antivirals |
| JP2024525164A (ja) | 2021-06-17 | 2024-07-10 | アテア ファーマシューティカルズ， インコーポレイテッド | 有利な抗ｈｃｖ併用療法 |
| AU2023227794A1 (en) | 2022-03-02 | 2024-10-17 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0533833B1 (en) | 1990-06-13 | 1995-12-20 | GLAZIER, Arnold | Phosphorous produgs |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| JP2003523978A (ja) | 2000-02-18 | 2003-08-12 | シャイアー・バイオケム・インコーポレイテッド | ヌクレオシドアナログを用いるｆｌａｖｉｖｉｒｕｓ感染の処置もしくは予防するための方法 |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| ATE491459T1 (de) | 2000-10-18 | 2011-01-15 | Pharmasset Inc | Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation |
| DZ3487A1 (fr) * | 2001-01-22 | 2002-07-25 | Merck Sharp & Dohme | Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant |
| US20040006002A1 (en) * | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| AT410792B (de) * | 2001-12-28 | 2003-07-25 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung |
| US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| BRPI0515279A (pt) | 2004-09-14 | 2008-07-15 | Pharmasset Inc | preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados |
| KR20070100237A (ko) * | 2004-10-29 | 2007-10-10 | 바이오크리스트 파마수티컬즈, 인코퍼레이티드 | 치료용 푸로피리미딘 및 티에노피리미딘 |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| AU2007338899A1 (en) | 2006-12-20 | 2008-07-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2124555B1 (en) | 2007-01-05 | 2015-07-08 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| SG177974A1 (en) | 2007-01-12 | 2012-02-28 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| WO2008141079A1 (en) | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer |
| WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
-
2010
- 2010-02-09 PE PE2016000564A patent/PE20161067A1/es not_active Application Discontinuation
- 2010-02-09 NZ NZ594370A patent/NZ594370A/en not_active IP Right Cessation
- 2010-02-09 PL PL10704068T patent/PL2396340T3/pl unknown
- 2010-02-09 MX MX2011008409A patent/MX2011008409A/es active IP Right Grant
- 2010-02-09 PT PT107040685T patent/PT2396340E/pt unknown
- 2010-02-09 ES ES13194605.5T patent/ES2628842T3/es active Active
- 2010-02-09 BR BRPI1013643A patent/BRPI1013643A2/pt active Search and Examination
- 2010-02-09 DK DK10704068.5T patent/DK2396340T3/en active
- 2010-02-09 SI SI201030554T patent/SI2396340T1/sl unknown
- 2010-02-09 EP EP10704068.5A patent/EP2396340B1/en active Active
- 2010-02-09 PT PT131946055T patent/PT2719701T/pt unknown
- 2010-02-09 ES ES10704068.5T patent/ES2453078T3/es active Active
- 2010-02-09 PE PE2011001464A patent/PE20120257A1/es active IP Right Grant
- 2010-02-09 HR HRP20140219AT patent/HRP20140219T1/hr unknown
- 2010-02-09 UA UAA201506736A patent/UA112140C2/uk unknown
- 2010-02-09 KR KR1020177008719A patent/KR101834707B1/ko not_active Expired - Fee Related
- 2010-02-09 AP AP2011005818A patent/AP2922A/xx active
- 2010-02-09 EP EP13194605.5A patent/EP2719701B1/en active Active
- 2010-02-09 US US12/702,957 patent/US8012942B2/en active Active
- 2010-02-09 MX MX2014007180A patent/MX345562B/es unknown
- 2010-02-09 JP JP2011549324A patent/JP5746638B2/ja not_active Expired - Fee Related
- 2010-02-09 AU AU2010213873A patent/AU2010213873B2/en not_active Ceased
- 2010-02-09 SG SG2011054798A patent/SG173186A1/en unknown
- 2010-02-09 EA EA201190110A patent/EA025085B1/ru not_active IP Right Cessation
- 2010-02-09 KR KR1020117020990A patent/KR101724759B1/ko not_active Expired - Fee Related
- 2010-02-09 WO PCT/US2010/023586 patent/WO2010093608A1/en not_active Ceased
- 2010-02-09 CN CN201080011690.0A patent/CN102348713B/zh not_active Expired - Fee Related
- 2010-02-09 PE PE2016000758A patent/PE20160858A1/es not_active Application Discontinuation
- 2010-02-09 CA CA2751277A patent/CA2751277C/en not_active Expired - Fee Related
- 2010-09-02 UA UAA201110568A patent/UA110093C2/ru unknown
-
2011
- 2011-08-02 IL IL214396A patent/IL214396A/en not_active IP Right Cessation
- 2011-08-09 CL CL2011001906A patent/CL2011001906A1/es unknown
- 2011-08-26 CO CO11109501A patent/CO6420354A2/es active IP Right Grant
-
2014
- 2014-04-28 SM SM201400056T patent/SMT201400056B/xx unknown
- 2014-07-07 JP JP2014139374A patent/JP5951690B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-06 AU AU2015238785A patent/AU2015238785B2/en not_active Ceased
-
2017
- 2017-04-12 AU AU2017202413A patent/AU2017202413B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012517444A5 (enExample) | ||
| JP2013538230A5 (enExample) | ||
| JP2011518835A5 (enExample) | ||
| JP2014514308A5 (enExample) | ||
| JP2011521903A5 (enExample) | ||
| ME02656B (me) | 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje | |
| JP6140815B2 (ja) | ウラシルスピロオキセタンヌクレオシド | |
| TWI543976B (zh) | Ｃ型肝炎病毒複製之新穎抑制劑 | |
| JP4624419B2 (ja) | 抗ウイルス性へテロ環化合物 | |
| CA2899763C (en) | Nucleoside phosphoramidate compound and use thereof | |
| JP2014503516A5 (enExample) | ||
| ES2449540T3 (es) | Inhibidores macrocíclicos del virus de la hepatitis C | |
| CA2706327C (en) | 2',4'-substituted nucleosides as antiviral agents | |
| JP6034883B2 (ja) | ヘテロ三環状部分を有する抗ウイルス性化合物 | |
| JP2013504593A5 (enExample) | ||
| JP2012519691A5 (enExample) | ||
| JP2007534636A5 (enExample) | ||
| JP2011511841A5 (enExample) | ||
| KR20180119669A (ko) | 항바이러스제에 의한 b형 간염 바이러스의 제거 | |
| HRP20140539T1 (hr) | Modulatori toll-sliäśnih receptora | |
| BRPI0614621A2 (pt) | inibidores macrocìclicos de vìrus da hepatite c | |
| TW201116540A (en) | Therapeutic antiviral peptides | |
| JP2012504632A5 (enExample) | ||
| KR20090079881A (ko) | Ｃ형 간염 바이러스의 마크로사이클릭 억제제 | |
| JP2014504643A5 (enExample) |